Form 4: Corcept Therapeutics CBO Reports Stock Transactions

Chief Business Officer Gary Charles Robb reported recent acquisitions and tax-related dispositions of Corcept Therapeutics common stock.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, acquired 776 shares of common stock at $70.44 per share on June 1, 2026, via a purchase plan.
• An additional 776 shares were acquired as unvested restricted stock awards under the same purchase plan.
• On June 2, 2026, 358 shares were withheld by the company to satisfy tax obligations related to the vesting of restricted stock units.
• Following these transactions, the reporting person holds 25,681 shares directly, plus additional indirect holdings in custodial accounts and a revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation activity with no material impact on company operations.

Positives

• The reporting person continues to maintain a significant equity stake in the company, signaling alignment with shareholder interests.
• The acquisition of shares through a formal purchase plan demonstrates active participation in the company's equity incentive programs.

Negatives

• The transaction involved a disposition of shares to cover tax withholding obligations, which is a standard but routine reduction in direct holdings.

Risks

• The vesting of restricted stock awards is contingent upon the reporting person remaining the beneficial owner of the purchase plan shares through the one-year anniversary date.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing instead on individual insider transaction reporting.

Industry Context

StockSavvy.ai notes that routine Form 4 filings regarding executive equity compensation are standard practice in the biotechnology sector and generally reflect internal confidence rather than shifts in corporate strategy.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans and standard tax withholding for equity vesting is consistent with corporate governance best practices for U.S. publicly traded companies.

Related Party Transactions

• The reporting person serves as custodian for custodial accounts held by their children and as trustee for the Robb Revocable Trust.

Stakeholder Impact

• Minimal impact on shareholders as these transactions represent standard executive compensation and tax management.

Next Steps

• Vesting of restricted stock awards on their respective one-year anniversary dates, subject to continued employment and ownership requirements.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Equity Compensation, SEC Filing